Documenting the effectiveness, safety, and acceptability of ulipristal acetate and misoprostol for medication abortion
Supports research on the effectiveness, safety, and acceptability of ulipristal acetate and misoprostol for medication abortion in the US to inform clinical and policy decisions.
Funder: Society of Family Planning
Due Dates: June 22, 2026 (Full proposal/application submission deadline)
Funding Amounts: Up to $150,000 per project for a 12-month period; up to two awards anticipated.
Summary: Supports research evaluating the effectiveness, safety, and acceptability of ulipristal acetate and misoprostol for medication abortion in the US.
Key Information: Projects must be completed within 12 months; only US-based, tax-exempt organizations are eligible.
Description
This grant opportunity, offered by the Society of Family Planning, aims to fund rigorous research projects that evaluate the effectiveness, safety, and acceptability of using ulipristal acetate (UPA) and misoprostol as an alternative regimen for medication abortion. The initiative responds to ongoing legal and regulatory challenges affecting standard abortion care regimens in the US, seeking to generate empirical data that can inform evidence-based, person-centered abortion care. Research may utilize a variety of study designs and settings—including telehealth and in-person clinics—and must address outcome measurement, feasibility, and legal context. The findings should have a clear path to influencing clinical practice, public policy, or health service delivery. The Society encourages applications from diverse teams and projects that reflect on the lived experiences and identities of research team members.
